Klinker H, Naumann U, Rössle M, et al. - between 2 August 2017 and 1 January 2020, efficacy and safety of 187 hepatitis C virus‐infected, treatment‐naïve, patients with compensated cirrhosis receiving 8‐week glecaprevir/pibrentasvir therapy in the German Hepatitis C‐Registry were compared. In this analysis, 98.4% (127/129) was sustained virologic response in the per‐protocol analysis (excluding patients lost to follow‐up or who discontinued treatment due to compliance) and was 85.8% (127/148) in patients with data available in an intention‐to‐treat analysis. In this real‐world analysis, eight‐week glecaprevir/pibrentasvir therapy was found to be effective and well‐tolerated.